Jupiter Life Line Hospitals Limited (JLHL) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Jupiter Life Line Hospitals Limited stock ₹130, price ₹257, that is 49.3% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
37‑month range ₹197.00 – ₹6,736 · fair‑value band ₹93.89 – ₹162.89 · the ₹257.15 price screens above the ₹130.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Jupiter Life Line Hospitals in your weekly email
Every Wednesday you see whether Jupiter Life Line Hospitals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India.
Show moreShow less
The company offers treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, endocrinology and diabetes, ENT, gastroenterology, general surgery and minimal access surgery, hematology and BMT, HPB and surgical gastroenterology, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, robotic surgery, TAVI/TAVR, and urology.
It also operates hotel under the Fortune Park Lake City Hotel brand in Thane. The company was incorporated in 2002 and is based in Mumbai, India.
Stock analysis
Jupiter Life Line Hospitals Limited (JLHL) currently trades at ₹257.15, while our model-based Fair Value estimate is ₹130.31, 49.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹168.72 per share, and 1 of the 16 models we run sit above the ₹257.15 price.
Bear case: the Asset-Based group reads lowest at ₹31.39, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹93.89 (bear) to ₹162.89 (bull), the price of ₹257.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Jupiter Life Line Hospitals Limited reported revenue of ₹15.0B in FY2026 versus ₹7.3B in FY2022, a compound +19.6%/yr. Reported net income was ₹1.9B in FY2026, compounding +39.6%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹84.1B (≈ $886M) · P/E ratio 46.8 · P/S ratio 5.20 · EPS (TTM) ₹5.49 · Dividend yield 0.1% · Net margin 11.5% · Return on equity 12.1% · Return on assets (EBIT) 13.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −49%, JLHL screens richer than that median.
Fair Value models
Bear₹93.89Fair Value ₹130.31Bull₹162.89
Price ₹257.15 · Downside -49.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹3.13 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+18.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.3%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.6%
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+35.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.3%
Dividend (yield on the price)0.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 17%
Compare Jupiter Life Line Hospitals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 235 stocks
Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−49.3% · Bottom 25%
Profitability
Return on equity (12 months)12.1% · Above median
Return on assets8.2% · Above median
Net margin (12 months)11.5% · Above median
Operating margin (12 months)17.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)16.0% · Top 25%
Dividend yield (12 months)0.1% · Bottom 25%
Balance sheet
Debt / equity0.32× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)46.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 35
FUTURE (revenue growth)80· sector 29
PAST (return on equity)48· sector 34
HEALTH (low debt)84· sector 90
DIVIDEND (yield)2· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jupiter Life Line Hospitals Limited Fair Value". https://www.fairvalue-calculator.com/stock/JLHL.NSE
Frequently asked questions
Is Jupiter Life Line Hospitals Limited (JLHL) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ₹130.31 versus a price of ₹257.15, about 49% lower (overvalued).
What is the fair value of JLHL?
Our model-based fair value for Jupiter Life Line Hospitals Limited is ₹130.31 (as of Nov 2, 2026), built from audited fundamentals. The current price: ₹257.15.
What is the quality score of JLHL?
Jupiter Life Line Hospitals Limited has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jupiter Life Line Hospitals Limited (JLHL)?
Our model-based price target is the fair value of ₹130.31 (as of Nov 2, 2026) from 16 valuation models. Cautious scenario ₹93.89, optimistic scenario ₹162.89. It is a calculation from audited fundamentals, not an analyst target.
What is the Jupiter Life Line Hospitals Limited stock forecast for 2026?
Our models put fair value at ₹130.31, about 49% lower versus a price of ₹257.15 (overvalued). Cautious scenario ₹93.89, optimistic scenario ₹162.89. The calculation is refreshed regularly with new filings.
What is the revenue of Jupiter Life Line Hospitals Limited (JLHL)?
Jupiter Life Line Hospitals Limited reported trailing-twelve-month revenue of about ₹16.2B (latest available figure, as of Nov 2, 2026).
Does Jupiter Life Line Hospitals Limited pay a dividend?
Jupiter Life Line Hospitals Limited currently shows a dividend yield of 0.08% relative to its recent price (as of Nov 2, 2026).
What is the intrinsic value of Jupiter Life Line Hospitals Limited (JLHL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jupiter Life Line Hospitals Limited it is ₹130.31 per share (as of Nov 2, 2026), against a price of ₹257.15. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Jupiter Life Line Hospitals Limited stock overvalued or undervalued in 2026?
As of Nov 2, 2026, JLHL trades above its calculated fair value: price ₹257.15, fair value ₹130.31, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JLHL?
No. The price is what the market pays today (₹257.15); the fair value is what the company's own numbers justify (₹130.31). For Jupiter Life Line Hospitals Limited the two are ₹126.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jupiter Life Line Hospitals Limited worth?
The market values Jupiter Life Line Hospitals Limited at about ₹84.1B (market capitalisation, as of Nov 2, 2026). Per share that is ₹257.15; our models calculate a fair value of ₹130.31 per share.
What do the bullish and bearish scenarios say about JLHL?
Our models span a range for Jupiter Life Line Hospitals Limited: cautious scenario ₹93.89, base ₹130.31, optimistic ₹162.89 per share (as of Nov 2, 2026, price ₹257.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JLHL?
Jupiter Life Line Hospitals Limited trades at a price-to-earnings ratio of 46.8 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹130.31 is built from several models across several years.
How solid is the balance sheet of Jupiter Life Line Hospitals Limited (JLHL)?
Balance-sheet figures for Jupiter Life Line Hospitals Limited (as of Nov 2, 2026): return on equity 12.1%, debt of 0.32 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is JLHL from its 52-week high?
Jupiter Life Line Hospitals Limited trades at ₹257.15, about 23% below its 52-week high of ₹332.40 and 7% above the low of ₹239.65 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of ₹130.31 is for.
Which stocks are comparable to Jupiter Life Line Hospitals Limited?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jupiter Life Line Hospitals Limited stock attractive at the current price?
The data as of Nov 2, 2026: price ₹257.15, calculated fair value ₹130.31 (−49%), Quality Score 46/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JLHL calculated?
We run Jupiter Life Line Hospitals Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹130.31, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Jupiter Life Line Hospitals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jupiter Life Line Hospitals Limited (JLHL)?
The closing price on Oct 30, 2026 was ₹257.15. Our model-based fair value is ₹130.31, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jupiter Life Line Hospitals Limited right now?
The price sits above even our optimistic bull case (₹162.89). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of Jupiter Life Line Hospitals Limited
How large is the market capitalisation of Jupiter Life Line Hospitals Limited (JLHL)?
The market capitalisation of Jupiter Life Line Hospitals Limited is ₹84.1B (≈ $886M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jupiter Life Line Hospitals Limited (JLHL)?
The price-to-sales ratio of Jupiter Life Line Hospitals Limited is 5.20 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jupiter Life Line Hospitals Limited (JLHL)?
Earnings per share at Jupiter Life Line Hospitals Limited are ₹5.49 (price ÷ EPS = P/E 46.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jupiter Life Line Hospitals Limited (JLHL)?
The dividend yield of Jupiter Life Line Hospitals Limited is 0.1% (payout 3.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jupiter Life Line Hospitals Limited (JLHL)?
The net margin of Jupiter Life Line Hospitals Limited is 11.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jupiter Life Line Hospitals Limited (JLHL)?
The return on equity (ROE) of Jupiter Life Line Hospitals Limited is 12.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jupiter Life Line Hospitals Limited (JLHL)?
On an EBIT basis the return on assets of Jupiter Life Line Hospitals Limited is 13.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jupiter Life Line Hospitals Limited (JLHL)?
The operating margin of Jupiter Life Line Hospitals Limited is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jupiter Life Line Hospitals Limited (JLHL)?
Revenue at Jupiter Life Line Hospitals Limited is growing +16.0% versus a year earlier (3y avg +18.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jupiter Life Line Hospitals Limited (JLHL)?
Earnings per share at Jupiter Life Line Hospitals Limited are growing −1.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jupiter Life Line Hospitals Limited (JLHL) generate?
The free cash flow of Jupiter Life Line Hospitals Limited is −₹2.3B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jupiter Life Line Hospitals Limited (JLHL) carry?
The net debt of Jupiter Life Line Hospitals Limited is ₹5.3B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jupiter Life Line Hospitals Limited in the live analysis
One click puts Jupiter Life Line Hospitals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 2, 2026